Bullous Pemphigoid Clinical Trials

⁃ ・ 3) Cancer-associated myositis

⁃ ・ 4) Significant muscle damage

⁃ ・ 5) Past history of severe Interstitial lung disease (ILD) flare, severe non-infectious lung inflammation which required active intervention, or multiple episodes of lung disease

⁃ ・ 6) Severe respiratory muscle weakness

⁃ ・ 7) Severe bulbar palsy

⁃ ・ 8) Treatment with prohibited medications

• ITP cohort:

⁃ ・ 1) Secondary ITP

⁃ ・ 2) Clinical diagnosis or history of Myelodysplastic Syndrome or autoimmune hemolytic anemia

⁃ ・ 3) History of venous or arterial thrombosis within 12 months

⁃ ・ 4) Patients who experienced major bleeding within 4 weeks

‣ 5\) Treatment with prohibited medications

‣ 6\) Any laboratory test results meet either of the following criteria at screening:

• Hemoglobin \<10 g/dL

∙ Thyroid-stimulating hormone \>= 10 μIU/mL